Benson Investment Management Company Inc. Makes New Investment in Hologic, Inc. (NASDAQ:HOLX)

Benson Investment Management Company Inc. purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 67,025 shares of the medical equipment provider's stock, valued at approximately $4,832,000. Hologic makes up about 2.0% of Benson Investment Management Company Inc.'s holdings, making the stock its 29th biggest position.

A number of other institutional investors have also recently bought and sold shares of the stock. Wolff Wiese Magana LLC acquired a new stake in shares of Hologic in the third quarter valued at approximately $25,000. General Partner Inc. acquired a new stake in shares of Hologic in the fourth quarter valued at approximately $26,000. First Horizon Advisors Inc. raised its holdings in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of Hologic in the second quarter valued at approximately $37,000. Finally, Cromwell Holdings LLC raised its holdings in shares of Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 416 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. Mizuho lowered their target price on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. Evercore ISI boosted their target price on shares of Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a report on Tuesday, October 1st. William Blair restated an "outperform" rating on shares of Hologic in a report on Monday. Finally, BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a report on Tuesday, December 10th. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $88.92.

Insider Activity

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. This represents a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.75% of the stock is currently owned by insiders.

Hologic Price Performance

HOLX traded down $0.09 on Tuesday, hitting $70.20. 2,612,914 shares of the stock were exchanged, compared to its average volume of 2,198,201. Hologic, Inc. has a 12 month low of $69.46 and a 12 month high of $84.67. The business has a 50-day moving average of $75.61 and a two-hundred day moving average of $78.53. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm has a market capitalization of $15.93 billion, a price-to-earnings ratio of 21.08, a PEG ratio of 2.32 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.89 earnings per share. Sell-side analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.